Structure-activity relationships of dynorphin A analogues modified in the address sequence

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2104-2109

  Schlechtingen, Georg ^a   DeHaven, Robert N ^b   Daubert, Jeffrey D ^b   Cassel, Joel A ^b   Chung, Nga N ^c   Schiller, Peter W ^c   Taulane, Joseph P ^a   Goodman, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ADOLOR CORPORATION   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMINO ACID; AMINO ACID DERIVATIVE; ARGININE; DYNORPHIN A DERIVATIVE; DYNORPHIN A[1-10][3 PROLINE]AMIDE; DYNORPHIN A[1-10]HYDROXIDE; DYNORPHIN A[1-11][3 PROLINE 8 ARGININE]AMIDE; DYNORPHIN A[1-11][3 PROLINE]AMIDE; DYNORPHIN A[1-11][3 PROLINE]HYDROXIDE; DYNORPHIN A[1-11]AMIDE; DYNORPHIN A[1-13]HYDROXIDE; DYNORPHIN A[1-5][3 PROLINE]AMIDE; DYNORPHIN A[1-5]HYDROXIDE; DYNORPHIN A[1-6][3 PROLINE]AMIDE; DYNORPHIN A[1-6]HYDROXIDE; DYNORPHIN A[1-7][3 PROLINE]AMIDE; DYNORPHIN A[1-7]HYDROXIDE; DYNORPHIN A[1-8][3 PROLINE]AMIDE; DYNORPHIN A[1-8]HYDROXIDE; DYNORPHIN A[1-9][3 PROLINE]AMIDE; DYNORPHIN A[1-9]HYDROXIDE; ISOLEUCINE; KAPPA OPIATE RECEPTOR; LIGAND; NALOXONE; OPIATE RECEPTOR; PROLINE; PROLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID ANALYSIS; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG MECHANISM; DRUG SELECTIVITY; ELECTRICITY; EXTRACELLULAR SPACE; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ANALGESICS, OPIOID; ANIMALS; CHO CELLS; CRICETINAE; DYNORPHINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUINEA PIGS; ILEUM; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038248848     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020125+     Document Type: Article

References (47)

1. Satoh, M.; Minami, M. Molecular Pharmacology of the Opioid Receptors. Pharmacol. Ther. 1995, 68, 343-364.
2. Knapp, R. J.; Malatynska, E.; Collins, N.; Fang, L.; Wang, J. Y.; Hruby, V. J.; Roeske, W. R.; Yamamura, H. I. Molecular Biology and Pharmacology of Cloned Opioid Receptors. FASEB J. 1995, 9, 516-525.
3. Kieffer, B. L. Recent Advances in Molecular Recognition and Signal Transduction of Active Peptides: Receptors for Opioid Peptides. Cell. Mol. Neurobiol. 1995, 15, 615-635.
4. Millan, M. J. κ-Opioid Receptors and Analgesia. Trends Pharmacol. Sci. 1990, 11, 70-76.
5. Székely, J. I., Ed. Opioid Peptides in Substance Abuse; CRC Press: Boca Raton, FL, 1994; pp 251-264.
6. Goldstein, A.; Tachibana, S.; Lowney, L. I.; Hunkapillar, M.; Hood, L. Dynorphin-(1-13), an Extraordinarily Potent Opioid Peptide. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 6666-6670.
7. Cox, B. M.; Openheim, K. E.; Teschenmacher, H.; Goldstein, A. A Peptide-Like Substance from Pituitary that Acts Like Morphine. 2. Purification and Properties. Life Sci. 1975, 16, 1777-1782.
8. Goldstein, A.; Fischli, W.; Lowney, L. I.; Hunkapillar, M.; Hood, L. Porcine Pituitary Dynorphin: Complete Amino Acid Sequence of the Biologically Active Heptadecapeptide. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 7219-7223.
9. Chavkin, C.; James, I. F.; Goldstein, A. Dynorphin Is a Specific Endogenous Ligand of the κ Opioid Receptor. Science (Washington D.C.) 1982, 215, 413-415.
10. Chavkin, C.; Goldstein, A. Specific Receptor for the Opioid Peptide Dynorphin: Structure-Activity Relationships. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 6543-6547.
11. Lung, F.-D. T.; Meyer, J.-P.; Li, G.; Lou, B.-S.; Stropova, D.; Davis, P.; Yamamura, H. I.; Porreca, F.; Hruby, V. J. Highly κ Receptor-Selective Dynorphin A Analogues with Modifications in Position 3 of Dynorphin A(1-11)-NH2. J. Med. Chem. 1995, 38, 585-586.
12. 2 on κ Receptor Selectivity and Potency. J. Med. Chem. 1996, 39, 2456-2460.
13. 10]dynorphin A-(1-11) Are Highly Selective for κ-Opioid Receptors. J. Med. Chem. 1992, 35, 4638-4639.
14. 10]-Dynorphin A(1-11) Analogues with N-Terminal Alkyl Substitution. J. Med. Chem. 1997, 40, 2733-2739.
15. 10]Dynorphin A-(1-11) Are High Affinity Partial Agonists at the Cloned Rat κ-Opioid Receptor. Eur. J. Pharmacol. 1997, 338, 191-197.
16. Hruby, V. J.; Collins, N.; Lung, F.-D. T.; Meyer, J.-P.; Davis, T. P.; Yamamura, H. I.; Porreca, F. Design of Peptides and Peptidomimetics for Delta and Kappa Opioid Receptor Subtypes. Regul. Pept. 1994, 54, 123-124.
17. 2: A Dynorphin Analogue with High Selectivity for the κ Opioid Receptor. J. Med. Chem. 2000, 43, 2698-2702.
18. Xue, J. C.; Chen, C.; Zhu, J.; Kunapuli, S.; DeRiel, J. K.; Yu, L.; Liu-Chen, L.-Y. Differential Binding Domains of Peptide and Non-Peptide Ligands in the Cloned Rat κ Opioid Receptor. J. Biol. Chem. 1994, 269, 30195-30199.
19. Wang, J. B.; Johnson, P. S.; Wu, J. M.; Wang, W. F.; Uhl, G. R. Human κ-Opioid Receptor Second Extracellular Loop Elevates Dynorphin's Affinity for Human μ/κ Chimeras. J. Biol. Chem. 1994, 269, 25966-25969.
20. Ferguson, D. M.; Kramer, S.; Metzger, T. G.; Law, P. Y.; Portoghese, P. S. Isosteric Replacement of Acidic with Neutral Residues in Extracellular Loop-2 of the κ-Opioid Receptor Does Not Affect Dynorphin A(1-13) Affinity and Function. J. Med. Chem. 2000, 43, 1351-1352.
21. Paterlini, G.; Portoghese, P. S.; Ferguson, D. M. Molecular Simulation of Dynorphin A-(1-10) Binding to Extracellular Loop 2 of the κ-Opioid Receptor. A Model for Receptor Activation. J. Med. Chem. 1997, 40, 3254-3262.
22. Sole, N. A.; Barany, G. Optimization of Solid-Phase Synthesis of [Ala8]-DynorphinA(1-17). J. Org. Chem. 1992, 57, 5399-5403.
23. Bradford, M. M. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein - Dye Binding. Anal. Biochem. 1976, 72, 248-254.
24. Selley, D. E.; Sim, L. J.; Xiao, R.; Liu, Q.; Childers, S. R. μ-Opioid Receptor-Stimulated Guanosine-5′-O-(γ-thio)-triphosphate Binding in Rat Thalamus and Cultured Cell Lines: Signal Transduction Mechanisms Underlying Agonist Efficacy. Mol. Pharmacol. 1997, 51, 87-96.
25. 35S]thio)triphosphate Binding to Membranes from Human Neuroblastoma SH-SY5Y Cells. Mol. Pharmacol. 1995, 47, 848-854.
26. Kawasaki, A. M.; Knapp, R. J.; Walton, A.; Wire, W. S.; Zalewska, T.; Yamamura, H. I.; Porreca, F. K.; Burks, T. F.; Hruby, V. J. Synthesis, Opioid Binding Affinities and Potencies of Dynorphin A Analogues Substituted in Positions 1, 6, 7, 8 and 10. Int. J. Pept. Protein Res. 1993, 42, 411-419.
27. Mansour, A.; Hoversten, M. T.; Taylor, L. P.; Watson, S. J.; Akil, H. The Cloned μ, δ and κ Receptors and Their Endogenous Ligands: Evidence for Two Opioid Peptide Recognition Cores. Brain Res. 1995, 700, 89-98.
28. Turcotte, A.; Lalonde, J. M.; St-Pierre, S.; Lemaire, S. Dynorphin(1-13) I. Structure - Function Relationships of Ala-Containing Analogs. Int. J. Pept. Protein Res. 1984, 23, 361-367.
29. 35S]GTPγS Binding to Cell Membranes. In Methods in Molecular Biology; Chaliss, R. A. J., Ed.; Humana Press Inc.; Totowa, NJ, 1997; Vol. 83, pp 107-116.
30. 35S]GTPγS Binding: A Tool To Evaluate Functional Activity of a Cloned Opioid Receptor Transiently Expressed in COS Cells. Neurochem. Res. 1996, 21, 1301-1307.
31. 3H]U69593. J. Neurochem. 1989, 53, 27-36.
32. 3H]Diprenorphine Binding to κ Sites in Guinea Pig and Rat Brain: Evidence for Apparent Heterogeneity. J. Neurochem. 1989, 53, 173-178.
33. Kenakin, T. Differences between Natural and Recombinant G Protein-Coupled Receptor Systems with Varying Receptor/G Protein Stoichiometry. Trends Pharmacol. Sci. 1997, 18, 456-464.
34. Kenakin, T. The Classification of Seven Transmembrane Receptors in Recombinant Expression Systems. Pharmacol. Rev. 1996, 48, 413-463.
35. 1B Receptor Expression System. Mol. Pharmacol. 1993, 43, 427-433.
36. Hoyer, D.; Boddeke, H. W. G. M. Partial Agonists, Full Agonists, Antagonists: Dilemmas of Definition. Trends Pharmacol. Sci. 1993, 14, 270-275.
37. 35S]GTPγS Binding in mMOR-CHO Cells and Rat Thalamus. J. Pharmacol. Exp. Ther. 1998, 285, 496-505.
38. Woolf, C. J. Analgesia and Hyperalgesia Produced in the Rat by Intrathecal Naloxone. Brain Res. 1980, 189, 593-597.
39. Levine, J. D.; Gordon, N. C.; Fields, H. L. Naloxone Dose Dependently Produces Analgesia and Hyperalgesia in Postoperative Pain. Nature 1979, 278, 740-741.
40. Crain, S. M.; Shen, K.-F. Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence during Chronic Cotreatment. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10540-10544.
41. Fukuda, K.; Kato, S.; Shoda, T.; Morikawa, H.; Mima, H.; Mori, K. Partial Agonistic Activity of Naloxone on the Opioid Receptors Expressed from Complementary Deoxyribonucleic Acids in Chinese Hamster Ovary Cells. Anesth. Analg. 1998, 87, 450-455.
42. 35S]GTPγS Binding to Membranes: Determination of Potencies and Efficacies of Ligands. J. Pharmacol. Exp. Ther. 1997, 282, 676-684.
43. Paton, W. D. M. The Action of Morphine and Related Substances on Contraction and on Acetylcholine Output of Coaxially Stimulated Guinea Pig Ileum. Br. J. Pharmacol. 1957, 12, 119-127.
44. Schiller, P. W.; Lipton, A.; Horrobin, D. F.; Bodanszky, M. Unsulfated C-Terminal 7-Peptide of Cholecystokinin: A New Ligand of the Opiate Receptor. Biochern. Biophys. Res. Commun. 1978, 85, 1332-1338.
45. Kosterlitz, H. W.; Watt, A. Kinetic Parameters of Narcotic Agonists and Antagonists with Particular Reference to N-Allylnoroxymorphone (Naloxone). Br. J. Pharmacol. 1968, 33, 266-276.
46. Meyer, J.-P.; Collins, N.; Lung, F.-D. T.; Davis, P.; Zalewska, T.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Design, Synthesis, and Biological Properties of Highly Potent Cyclic Dynorphin A Analogues. Analogues Cyclized between Positions 5 and 11. J. Med. Chem. 1994, 37, 3910-3917.
47. 2. J. Med. Chem. 1996, 39, 1136-1141.